Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Dec 31;14(12):3799-3805.
doi: 10.21037/tau-2025-587. Epub 2025 Dec 22.

Impact of durable response of first-line systemic treatment for patients with locally advanced or metastatic urothelial carcinoma: data update of EV-302/KEYNOTE-A39 trial

Makito Miyake  1
Affiliations
Editorial

Impact of durable response of first-line systemic treatment for patients with locally advanced or metastatic urothelial carcinoma: data update of EV-302/KEYNOTE-A39 trial

Makito Miyake. Transl Androl Urol. .
No abstract available

Keywords: Combination; durable response; enfortumab vedotin (EV); pembrolizumab; urothelial carcinoma (UC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-587/coif). M.M. received honoraria from MSD K.K., Ono Pharmaceutical CO., LTD., and Astellas Pharma Inc.; served in a consulting or advisory role for MSD K.K., Ono Pharmaceutical CO., LTD., and Astellas Pharma Inc. The author has no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Kaplan-Meier estimates of (A) PFS in the overall population, (B) OS in the overall population, (C) duration of response for patients with the best overall response of CR or PR, and (D) duration of response for patients with the best overall response of CR in the EV-302 trial. Image reproduced with permission from Elsevier (14). a, P value is nominal and descriptive. CI, confidence interval; CR, complete response; EV + P, enfortumab vedotin plus pembrolizumab combination therapy; HR, hazard ratio; OS, overall survival; PD, progessive disease; PFS, progression-free survival; PR, partial response; NE, not estimable; NR, not reached.
See this image and copyright information in PMC

Comment on

References

    1. Soualhi A, Rammant E, George G, et al. The incidence and prevalence of upper tract urothelial carcinoma: a systematic review. BMC Urol 2021;21:110. 10.1186/s12894-021-00876-7 - DOI - PMC - PubMed
    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. 10.3322/caac.21660 - DOI - PubMed
    1. Zhang Y, Rumgay H, Li M, et al. The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. J Glob Health 2023;13:04109. 10.7189/jogh.13.04109 - DOI - PMC - PubMed
    1. Matsuda T, Okuyama A. Incidence rate for bladder cancer in Japanese in Japan and in the United States from the Cancer Incidence in Five Continents. Jpn J Clin Oncol 2017;47:284-5. 10.1093/jjco/hyx017 - DOI - PubMed
    1. Miyake M, Nishimura N, Shimizu T, et al. Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data. Cancer Manag Res 2022;14:623-35. 10.2147/CMAR.S348899 - DOI - PMC - PubMed